Electra Therapeutics IPO Pricing: $350 Million at $15 a Share
Electra Therapeutics priced 23.3 million shares at $15 in its September 2026 Nasdaq IPO. Our review of the 424B4 prospectus, pipeline, losses and cash.
Key takeaways
- Electra Therapeutics set its IPO pricing at $15.00 per share, selling 23,333,334 shares for about $350 million in gross proceeds, according to its 424B4 prospectus filed September 18, 2026.
- Net proceeds to the company were about $325.5 million after a $1.05 per share underwriting discount.
- The shares were set to list on the Nasdaq Global Select Market under the ticker ETRA.
- The lead program, ipsoprubart, is in a Phase 2/3 registrational trial for secondary hemophagocytic lymphohistiocytosis.
- Net loss widened to $48.9 million in the first half of 2026, and cash stood at $97.7 million on June 30, 2026.
The IPO pricing terms
Electra describes itself as a late clinical-stage biopharmaceutical company developing precision medicines for immune-mediated diseases and cancer. Its prospectus, dated September 17, 2026, states this was its first public offering and that no public market for its common stock existed beforehand.
| Item | Figure |
|---|---|
| Shares offered | 23,333,334 |
| Price per share | $15.00 |
| Gross proceeds | $350,000,010 |
| Underwriting discount | $1.05/share ($24.5 million) |
| Net proceeds to company | $325,500,009 |
| Underwriters’ option | 3,500,000 shares |
| Shares outstanding after IPO | 62,766,955 |
The 7% underwriting discount is the conventional spread for a mid-size biotech IPO. Jefferies, TD Cowen, Evercore ISI and Cantor led the deal.
IPO valuation at the offering price
With 62,766,955 shares outstanding after the offering, the $15 price implies a market capitalization of about $941 million before any option exercise. That is our arithmetic from the filing, and it ignores outstanding options and warrants. Full exercise of the underwriters’ option would lift the count to 66,266,955 shares.
A useful lens for biotech pricing is how much of that value is cash. Adding the June 30 cash balance of $97.7 million to the net IPO proceeds gives roughly $423 million of pro forma cash, before expenses and spending after June 30. On that basis, cash would represent a meaningful share of the implied market value, with the remainder reflecting what buyers assigned to the pipeline.
The pipeline behind the price
The prospectus centers on two antibody programs:
- Ipsoprubart, a pan-SIRP monoclonal antibody, in a Phase 2/3 registrational trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe and often life-threatening inflammatory condition.
- ELA822, a SIRP-gamma-specific antibody, in Phase 1 for chronic T cell-mediated immune disorders.
Having a program in a registrational study is the main reason the company characterizes itself as late-stage. It also concentrates risk: the outcome of that trial is likely to drive the company’s prospects more than any other single event.
How the pricing compares
Electra’s $15 price and 7% spread match the terms seen in several other biotech IPOs this year, and the company sold only new shares, so every dollar raised went to fund operations rather than to cash out existing holders. That structure is typical for clinical-stage companies, which rely on primary capital to reach their next data readouts. The size of the raise relative to the June 30 cash balance, more than three times larger, shows how much of the company’s near-term plan depended on completing the offering.
Losses and runway
The financial data show spending rising as the lead program advanced:
- Year ended Dec. 31, 2024: net loss of $24.8 million
- Year ended Dec. 31, 2025: net loss of $62.0 million
- Six months ended June 30, 2025: net loss of $25.4 million
- Six months ended June 30, 2026: net loss of $48.9 million
The accumulated deficit reached $221.9 million at June 30, 2026. The first-half 2026 loss nearly doubled the prior-year period, a pattern typical of companies running a pivotal trial.
What to watch
The key items are the timing of data from the ipsoprubart registrational trial, whether the underwriters exercise their 3.5 million share option, how quickly quarterly losses grow from the first-half 2026 rate, and any partnership activity around ELA822.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.
